Autopsy report · NCT05572684

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

“Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 7 months before it stopped.
• 97 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

NextCure, Inc.

Sponsor type

Industry

Conditions

Advanced or Metastatic Solid Tumors; Microsatellite Instability Low; Microsatellite Instability High; Microsatellite Stable; Ovarian Cancer; Gastric Cancer

Interventions

NC410; pembrolizumab

Participants

97

Sites

17

Countries

United States

Trials that died the same way

• A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
  “The sponsor decided not to conduct the expansion part of trial (part 2)” (85% match in meaning)
• Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)
  “PI and Sponsor decided to not proceed with the trial.” (76% match in meaning)
• CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
  “Sponsor decision to not initiate the trial” (76% match in meaning)
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
  “Sponsor decision not to start trial” (75% match in meaning)
• Reparixin in COVID-19 Pneumonia - Efficacy and Safety
  “The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.